{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T17:52:09Z","timestamp":1775929929520,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jocn.2023.09.023","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T01:20:00Z","timestamp":1697246400000},"page":"16-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Clinical features, treatments, their impact, and quality of life for Myasthenia Gravis patients in Australia"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-5724","authenticated-orcid":false,"given":"Janet","family":"Sansoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lachlan","family":"Viali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Vucic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jocn.2023.09.023_b0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jocn.2023.09.023_b0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.09.023_b0015","first-page":"159","article-title":"Myasthenia gravis","volume":"88","author":"Vincent","year":"2002","journal-title":"Adv Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2023.09.023_b0020","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2023.09.023_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"198","author":"Andersen","year":"2014","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.jocn.2023.09.023_b0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The epidemiology of myasthenia gravis","volume":"998","author":"Phillips","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2023.09.023_b0035","doi-asserted-by":"crossref","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.J Clin Med. 2021;10(11):2235. Published 2021 May 21. doi:10.3390\/jcm10112235.","DOI":"10.3390\/jcm10112235"},{"issue":"11","key":"10.1016\/j.jocn.2023.09.023_b0040","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1468-1331.2012.03698.x","article-title":"A national epidemiological study of Myasthenia Gravis in Australia","volume":"19","author":"Gattellari","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2023.09.023_b0045","unstructured":"The Centre for International Economics. The cost to patients and the community of Myasthenia Gravis: Understanding the patient experience and community wide impact, 2014. Available: http:\/\/www. thecie. com. au\/ wp- content\/ uploads\/ 2014\/ 06\/ Final- report_Economic- Impact- of- Myasthenia- Gravis- 08112013. pdf [Accessed Feb 2023]."},{"key":"10.1016\/j.jocn.2023.09.023_b0050","doi-asserted-by":"crossref","unstructured":"Bacci ED, Coyne, KS, Poon, JL.et al.Understanding side effects of therapy for myasthenia gravis and their impact on daily life.BMC Neurol19, 335 (2019). doi.org\/10.1186\/s12883-019-1573-2.","DOI":"10.1186\/s12883-019-1573-2"},{"issue":"6","key":"10.1016\/j.jocn.2023.09.023_b0055","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jocn.2023.09.023_b0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"MG Composite and MG-QOL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2023.09.023_b0065","unstructured":"Myasthenia Gravis Foundation of America. Resources for Professionals. Myasthenia Gravis Foundation of America. accessed Dec 19, 2022. https:\/\/myasthenia.org\/Professionals\/Resources-for-Professionals."},{"issue":"1","key":"10.1016\/j.jocn.2023.09.023_b0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jnnp-2011-301449","article-title":"Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis","volume":"84","author":"Barnett","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jocn.2023.09.023_b0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/NRL.0000000000000238","article-title":"Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease","volume":"24","author":"Stojanov","year":"2019","journal-title":"Neurologist"},{"key":"10.1016\/j.jocn.2023.09.023_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"REDCap Consortium, The REDCap consortium: Building an international community of software partners","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jocn.2023.09.023_b0085","unstructured":"IBM Corp. Released 2021. IBM SPSS Statistics for Windows, Version 29.0. Armonk, NY."},{"issue":"1","key":"10.1016\/j.jocn.2023.09.023_b0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.20982\/tqmp.12.1.p030","article-title":"Why Welch\u2019s test is Type I error robust","volume":"12","author":"Derrick","year":"2016","journal-title":"TQMP"},{"key":"10.1016\/j.jocn.2023.09.023_b0095","unstructured":"Naji A, Owens ML. Edrophonium. In:StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554566\/."},{"issue":"4","key":"10.1016\/j.jocn.2023.09.023_b0100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.nmd.2018.12.011","article-title":"Evaluation and validation of sustained upgaze combined with the ice-pack test for ocular myasthenia gravis in Asians","volume":"29","author":"Kee","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.jocn.2023.09.023_b0105","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/jcm10081736","article-title":"Diagnosis of Myasthenia Gravis","volume":"10","author":"Rousseff","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.jocn.2023.09.023_b0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2023.09.023_b0115","doi-asserted-by":"crossref","unstructured":"Schroeter M, Thayssen G, Kaiser J. Myasthenia Gravis \u2013 Exacerbation and Crisis. Neurology International Open. 2018;2: E10-E15.","DOI":"10.1055\/s-0043-118441"},{"key":"10.1016\/j.jocn.2023.09.023_b0120","unstructured":"Bird S, Levine J, Shefner J, et al. Myasthenic Crisis. UpToDate. Jan 2023. Accessed Mar 23, 2023. https:\/\/www.uptodate.com\/contents\/myasthenic-crisis#H14."},{"key":"10.1016\/j.jocn.2023.09.023_b0125","series-title":"Using Multivariate Statistics","author":"Tabachnick","year":"2013"},{"key":"10.1016\/j.jocn.2023.09.023_b0130","unstructured":"Statista Research Department. Population Distribution Australia 2021, by state. Statista. Jan 2023. Accessed Oct 15, 2022, https:\/\/www.statista.com\/statistics\/608819\/australia-population-distribution-by-state\/."},{"issue":"5","key":"10.1016\/j.jocn.2023.09.023_b0135","first-page":"157","article-title":"Myasthenia gravis im Grenzgebiet psychiatrischer Diagnostik [Myasthenia gravis in the frontier of psychiatric diagnosis]","volume":"19","author":"Rohr","year":"1992","journal-title":"Psychiatr Prax"},{"issue":"6","key":"10.1016\/j.jocn.2023.09.023_b0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","article-title":"Seronegative myasthenia gravis: disease severity and prognosis","volume":"12","author":"Romi","year":"2005","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2023.09.023_b0145","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2023.09.023_b0150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm-19-363","article-title":"Serological diagnosis of myasthenia gravis and its clinical significance","volume":"11","author":"Li","year":"2023","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.jocn.2023.09.023_b0155","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current Treatment of Myasthenia Gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jocn.2023.09.023_b0160","doi-asserted-by":"crossref","unstructured":"Johnson S, Katyal N, Narula N, Govindarajan R. Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.Med Sci Monit. 2021;27:e933296. Published 2021 Oct 28. doi:10.12659\/MSM.933296.","DOI":"10.12659\/MSM.933296"},{"key":"10.1016\/j.jocn.2023.09.023_b0165","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid Adverse Effects. In:StatPearls. Treasure Island (FL): StatPearls Publishing; July 4, 2022. Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531462\/."},{"key":"10.1016\/j.jocn.2023.09.023_b0170","doi-asserted-by":"crossref","unstructured":"Ipe TS, Davis AR, Raval JS. Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence.Front Neurol. 2021;12:662856. Published 2021 Aug 31. doi:10.3389\/fneur.2021.662856.","DOI":"10.3389\/fneur.2021.662856"},{"key":"10.1016\/j.jocn.2023.09.023_b0175","doi-asserted-by":"crossref","unstructured":"Klemencic Kozul T, Yudina A, Donovan C, Pinto A, Osman C. Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions.BMC Health Serv Res. 2022;22(1):904. Published 2022 Jul 12. doi:10.1186\/s12913-022-08210-z.","DOI":"10.1186\/s12913-022-08210-z"},{"issue":"1","key":"10.1016\/j.jocn.2023.09.023_b0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.transci.2016.01.003","article-title":"Adverse events in apheresis: An update of the WAA registry data","volume":"54","author":"M\u00f6rtzell Henriksson","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"6","key":"10.1016\/j.jocn.2023.09.023_b0185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized Trial of Thymectomy in Myasthenia Gravis [published correction appears in N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text]","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jocn.2023.09.023_b0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.09.023_b0195","doi-asserted-by":"crossref","unstructured":"Petersson M, Feresiadou A, Jons D, et al. Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study [published online ahead of print, 2021 Aug 10] [published correction appears in Neurology. 2021 Dec 14;97(24):1141].Neurology. 2021;97(14):e1382-e1391. doi:10.1212\/WNL.0000000000012604.","DOI":"10.1212\/WNL.0000000000013021"},{"key":"10.1016\/j.jocn.2023.09.023_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: A systematic literature review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2023.09.023_b0205","doi-asserted-by":"crossref","unstructured":"Dewilde S, Philips G, Paci S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.BMJ Open. 2023;13(1):e066445. Published 2023 Jan 31. doi:10.1136\/bmjopen-2022-066445.","DOI":"10.1136\/bmjopen-2022-066445"},{"issue":"7","key":"10.1016\/j.jocn.2023.09.023_b0210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic Costs of Myasthenia Gravis: A Systematic Review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jocn.2023.09.023_b0215","doi-asserted-by":"crossref","unstructured":"Berrih-Aknin S, Claeys KG, Law N, et al. Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG).BMJ Open. 2021;11(7):e048198. Published 2021 Jul 20. doi:10.1136\/bmjopen-2020-048198.","DOI":"10.1136\/bmjopen-2020-048198"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:33:40Z","timestamp":1760823220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586823002850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"alternative-id":["S0967586823002850"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2023.09.023","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features, treatments, their impact, and quality of life for Myasthenia Gravis patients in Australia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2023.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}